drugset / Trial / NCT06785090

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

NCT06785090

Phase 4 Completed 87 enrolled Inas Abd
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if bromfenac ophthalmic solution can prevent cystoid macular edema (CME) and reduce macular thickness in patients undergoing phacoemulsification surgery for cataract removal. The main questions it aims to answer are: Does bromfenac reduce the incidence of CME after cataract surgery? Does bromfenac effectively control macular thickness postoperatively compared to standard care? investigators will compare the effects of bromfenac ophthalmic solution to a control group receiving standard postoperative treatment to see if bromfenac provides additional benefits. Participants will: Use bromfenac ophthalmic solution as prescribed postoperatively. Attend follow-up visits for macular thickness measurements and assessments of eye health. Undergo routine postoperative evaluations to monitor for adverse effects.

Timeline

Start
2023-05-01
Primary completion
2024-01-31
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bromfenac Other / unclassified 0.09 % Topical
Background Dexamethasone Small molecule 0.1 % Topical
Background Moxifloxacin Small molecule 0.5 % Topical